HK-listed gold stocks jump as US economic fears boost bullion prices
LOS ANGELES - Niagen Bioscience, Inc. (NASDAQ: NAGE), previously known as ChromaDex Corp., announced the expansion of its clinical presence with new clinics offering Niagen® IV, a patented nicotinamide riboside (NR) therapy. This network now includes nearly 600 clinics across the United States, providing a pharmaceutical-grade option for NAD+ boosting to patients. The company, currently valued at $623 million, has demonstrated strong financial performance with a 111% return over the past year. According to InvestingPro analysis, the company maintains healthy liquidity with a current ratio of 3.57, indicating strong operational stability.
Niagen IV has been shown to outperform traditional NAD+ IV therapy in several ways. It is reported to be more tolerable for patients, requires a 75% shorter infusion time, and has been found to increase NAD+ levels by 20% higher than NAD+ IV three hours post-infusion. These findings are based on a study that used NAD+ dried blood spot tests to measure the increase.
The company emphasizes that Niagen is an efficient NAD+ precursor, capable of crossing cell membranes directly and requiring fewer steps to convert into NAD+. This is in contrast to the common belief that NAD+ itself is bioavailable and can be taken orally or intravenously for direct benefits.
Niagen Bioscience ensures that their Niagen IV and injection products meet high-quality standards and regulatory compliance by partnering with FDA-registered 503B outsourcing facilities. These facilities adhere to the U.S. FDA guidelines, including the U.S. Pharmacopoeia (USP) for particulate matter and bacterial endotoxin testing. This quality-focused approach has contributed to the company’s impressive 61.8% gross profit margin and sustained revenue growth of 19.2% over the past year. For detailed analysis of NAGE’s financial health and growth prospects, investors can access comprehensive research through InvestingPro, which offers exclusive insights and 12+ additional ProTips about the company’s performance.
Clinics offering Niagen IV, such as Arete Wellness in Nashville and Beyond Remedi in Saint Paul, have reported positive feedback from their clients, particularly among high-performing professionals and athletes who seek to improve their health and performance.
Niagen Bioscience, recognized for its leadership in NAD+ science and healthy-aging research, continues to work with scientists and research institutions globally to explore the potential of NAD+ in supporting healthspan. Their product portfolio is centered around Niagen®, the patented form of NR, which is also the active ingredient in their consumer supplement, Tru Niagen®, and their pharmaceutical-grade IV and injectable products available through Niagen Plus™. The company’s financial success is reflected in its positive EBITDA of $8.54 million and strong operational metrics. Investors seeking deeper insights can access NAGE’s complete financial analysis and Fair Value assessment through InvestingPro’s detailed research reports, available as part of the platform’s coverage of 1,400+ US equities.
The expansion of Niagen IV therapy is part of the company’s ongoing efforts to provide innovative health solutions and is based on a press release statement by Niagen Bioscience, Inc.
In other recent news, Niagen Bioscience has reported several key developments. The company has expanded its intellectual property portfolio by securing a U.S. patent for various forms of nicotinamide riboside (NR) salts, which are critical for cellular health. This patent, licensed from Queen’s University Belfast, grants exclusive rights to these NR salt forms until 2034. Additionally, H.C. Wainwright has maintained its Buy rating for Niagen Bioscience with a price target of $11, highlighting the company’s resilience amid global tariffs and its robust U.S.-based supply chain. The firm’s analysts are optimistic about the potential expansion of Niagen’s NR franchise into prescription pharmaceuticals.
Furthermore, Niagen Bioscience has appointed Dr. Pinchas Cohen, a respected expert in gerontology and mitochondrial biology, to its Scientific Advisory Board. This move is expected to enhance the company’s research in NAD+ and aging-related diseases. The company’s CEO, Rob Fried, emphasized the strategic importance of maintaining a stable U.S.-based supply chain, which has shielded operations from international trade volatility. Niagen Bioscience’s product line, including Tru Niagen® and Niagen Plus™, continues to lead the NAD+ supplement market. These recent developments reflect the company’s ongoing commitment to innovation and stability in the healthy aging sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.